BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 26504053)

  • 21. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study.
    Oberlin O; Rey A; Sanchez de Toledo J; Martelli H; Jenney ME; Scopinaro M; Bergeron C; Merks JH; Bouvet N; Ellershaw C; Kelsey A; Spooner D; Stevens MC
    J Clin Oncol; 2012 Jul; 30(20):2457-65. PubMed ID: 22665534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Rhabdomyosarcoma in middle to old-aged patients: analysis of clinicopathological features and prognosis in 76 cases].
    Yu L; Wang J
    Zhonghua Zhong Liu Za Zhi; 2012 Dec; 34(12):910-6. PubMed ID: 23336377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ewing's sarcoma of the axial system in patients older than 15 years: dismal prognosis despite intensive multiagent chemotherapy and aggressive local treatment.
    Argon A; Basaran M; Yaman F; Dizdar Y; Sakar B; Camlica H; Bavbek SE; Ozger H; Darendeliler E; Onat H
    Jpn J Clin Oncol; 2004 Nov; 34(11):667-72. PubMed ID: 15613556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study.
    Bertuzzi A; Castagna L; Nozza A; Quagliuolo V; Siracusano L; Balzarotti M; Compasso S; Alloisio M; Soto Parra H; Santoro A
    J Clin Oncol; 2002 Apr; 20(8):2181-8. PubMed ID: 11956280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rhabdomyosarcoma: the experience of the pediatric unit of Kasr El-Aini Center of Radiation Oncology and Nuclear Medicine (NEMROCK) (from January 1992 to January 2001).
    Abd El-Aal HH; Habib EE; Mishrif MM
    J Egypt Natl Canc Inst; 2006 Mar; 18(1):51-60. PubMed ID: 17237856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The predictive value of initial cytostatic response in primary unresectable rhabdomyosarcoma in children.
    Treuner J; Suder J; Keim M; Kaatsch P; Niethammer D
    Acta Oncol; 1989; 28(1):67-72. PubMed ID: 2706134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumour volume reduction after neoadjuvant chemotherapy impacts outcome in localised embryonal rhabdomyosarcoma.
    Dantonello TM; Stark M; Timmermann B; Fuchs J; Selle B; Linderkamp C; Handgretinger R; Hagen R; Feuchtgruber S; Kube S; Kosztyla D; Kazanowska B; Ladenstein R; Niggli F; Ljungman G; Bielack SS; Klingebiel T; Koscielniak E;
    Pediatr Blood Cancer; 2015 Jan; 62(1):16-23. PubMed ID: 25263634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89.
    Stevens MC; Rey A; Bouvet N; Ellershaw C; Flamant F; Habrand JL; Marsden HB; Martelli H; Sanchez de Toledo J; Spicer RD; Spooner D; Terrier-Lacombe MJ; van Unnik A; Oberlin O
    J Clin Oncol; 2005 Apr; 23(12):2618-28. PubMed ID: 15728225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study.
    Wessalowski R; Schneider DT; Mils O; Friemann V; Kyrillopoulou O; Schaper J; Matuschek C; Rothe K; Leuschner I; Willers R; Schönberger S; Göbel U; Calaminus G;
    Lancet Oncol; 2013 Aug; 14(9):843-52. PubMed ID: 23823158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment and prognosis of stage IV alveolar soft part sarcoma].
    Zhao J; Yang Y
    Zhonghua Zhong Liu Za Zhi; 2012 Dec; 34(12):932-6. PubMed ID: 23336381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84.
    Flamant F; Rodary C; Rey A; Praquin MT; Sommelet D; Quintana E; Theobald S; Brunat-Mentigny M; Otten J; Voûte PA; Habrand JL; Martelli H; Barrett A; Terrier-Lacombe MJ; Oberlin O
    Eur J Cancer; 1998 Jun; 34(7):1050-62. PubMed ID: 9849454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
    Havemann K; Wolf M; Drings P; Hans K; Schroeder M; Holle R; Flechtner H; Goerg R; Becker H
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):9-18. PubMed ID: 2539648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of dose intensity of vincristine, d-actinomycin, and cyclophosphamide chemotherapy for child and adult rhabdomyosarcoma: a retrospective analysis.
    Kojima Y; Hashimoto K; Ando M; Yonemori K; Yamamoto H; Kodaira M; Yunokawa M; Shimizu C; Tamura K; Hosono A; Makimoto A; Fujiwara Y
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):391-7. PubMed ID: 22806306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
    Paulussen M; Craft AW; Lewis I; Hackshaw A; Douglas C; Dunst J; Schuck A; Winkelmann W; Köhler G; Poremba C; Zoubek A; Ladenstein R; van den Berg H; Hunold A; Cassoni A; Spooner D; Grimer R; Whelan J; McTiernan A; Jürgens H;
    J Clin Oncol; 2008 Sep; 26(27):4385-93. PubMed ID: 18802150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of ifosfamide and doxorubicin given as a phase II "window" in children with newly diagnosed metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group.
    Sandler E; Lyden E; Ruymann F; Maurer H; Wharam M; Parham D; Link M; Crist W
    Med Pediatr Oncol; 2001 Nov; 37(5):442-8. PubMed ID: 11745872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma.
    Lashkari A; Chow WA; Valdes F; Leong L; Phan V; Twardowski P; Kapoor N; Molina A; Al-Kadhimi Z; Frankel P; Somlo G
    Anticancer Res; 2009 Aug; 29(8):3281-8. PubMed ID: 19661346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of palliative chemotherapy in advanced epithelioid sarcoma.
    Jones RL; Constantinidou A; Olmos D; Thway K; Fisher C; Al-Muderis O; Scurr M; Judson IR
    Am J Clin Oncol; 2012 Aug; 35(4):351-7. PubMed ID: 21422990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
    Antman K; Crowley J; Balcerzak SP; Kempf RA; Weiss RB; Clamon GH; Baker LH
    Cancer; 1998 Apr; 82(7):1288-95. PubMed ID: 9529020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
    Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
    Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.